Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Open in Screener

TARS

Tarsus Pharmaceuticals Inc

Nov 28 • 02:20PM ET

79.96

-0.54 -0.67 %

Healthcare • Biotechnology • USA • NASD

Peers: XENE FOLD RDUS VKTX SRPT AXSM BTAI PRTA APLT PTCT

| Held by: VTI IWM VXF IWO IBB SCHA VTWO PJP IHE XPH

Index	RUT	P/E	-	EPS (ttm)	-2.01	Insider Own	7.88%	Shs Outstand	42.45M	Perf Week	3.87%
Market Cap	3.39B	Forward P/E	44.74	EPS next Y	1.79	Insider Trans	-2.09%	Shs Float	39.10M	Perf Month	18.42%
Enterprise Value	3.07B	PEG	-	EPS next Q	-0.10	Inst Own	104.93%	Short Float	18.33%	Perf Quarter	36.50%
Income	-81.16M	P/S	9.27	EPS this Y	51.83%	Inst Trans	-4.20%	Short Ratio	11.97	Perf Half Y	86.17%
Sales	366.10M	P/B	10.13	EPS next Y	220.84%	ROA	-17.82%	Short Interest	7.17M	Perf YTD	44.41%
Book/sh	7.89	P/C	8.45	EPS next 5Y	-	ROE	-28.35%	52W High	83.47 -4.21%	Perf Year	65.48%
Cash/sh	9.47	P/FCF	-	EPS past 3/5Y	-65.92% -66.60%	ROIC	-19.44%	52W Low	38.51 107.63%	Perf 3Y	370.08%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.49% -	Gross Margin	93.26%	Volatility	4.93% 4.87%	Perf 5Y	247.65%
Dividend TTM	-	EV/Sales	8.40	EPS Y/Y TTM	47.21%	Oper. Margin	-23.88%	ATR (14)	3.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.25	Sales Y/Y TTM	182.44%	Profit Margin	-22.17%	RSI (14)	64.94	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	4.29	EPS Q/Q	51.59%	SMA20	7.35%	Beta	0.74	Target Price	86.11
Payout	-	Debt/Eq	0.25	Sales Q/Q	146.68%	SMA50	15.94%	Rel Volume	0.20	Prev Close	80.50
Employees	323	LT Debt/Eq	0.25	Earnings	Nov 04 AMC	SMA200	52.85%	Avg Volume	598.94K	Price	79.96
IPO	Oct 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.14% 3.01%	Trades		Volume	120,659	Change	-0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-25	Initiated	Mizuho	Outperform	$100
Jun-02-25	Resumed	Oppenheimer	Outperform	$75
May-27-25	Resumed	H.C. Wainwright	Buy	$72
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Nov-24-25 04:30PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-05-25 05:05PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire)
12:04AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-04-25 05:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
07:31AM	Loading…
Nov-03-25 07:31AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-28-25 05:00PM	Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire)
Oct-09-25 09:27AM	Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? (Zacks)
Oct-06-25 06:41AM	Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Aug-27-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 06:33PM	3 Biotech Catalysts Present Major Opportunity (MarketBeat)
Aug-15-25 10:04AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily)
Aug-14-25 02:48PM	Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point. (Investor's Business Daily)
Aug-06-25 06:00PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +15.15%
04:05PM	Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
09:48AM	Loading…
Aug-05-25 09:48AM	Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result (GuruFocus.com)
Jul-30-25 05:00PM	Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
May-29-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 09:45AM	Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-08-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-05-25 06:04PM	Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts (Insider Monkey)
May-02-25 03:17AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com) -5.84%
May-01-25 09:37PM	Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Apr-30-25 10:17AM	Will Declining Medical Customers Affect Cigna's Q1 Earnings? (Zacks)
09:55AM	Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? (Zacks)
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-24-25 05:00PM	Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (GlobeNewswire)
11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
01:41PM	Loading…
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks)
08:31AM	Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting (GlobeNewswire)
Apr-21-25 04:05PM	Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders (Business Wire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-12-25 09:49PM	Tarsus Announces Pricing of Upsized $125.0 Million Public Offering (GlobeNewswire)
04:12PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Mar-06-25 05:00PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire) +6.66%
Feb-26-25 02:13AM	Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-25-25 08:40AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
01:31AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 05:00PM	Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 (GlobeNewswire)
Jan-30-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-20-25 03:31PM	Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Jan-14-25 09:35AM	Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround (Zacks) -5.72%
Jan-13-25 08:30AM	Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care (GlobeNewswire) -10.76%
Dec-26-24 10:30AM	How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run (Investor's Business Daily)
Dec-04-24 09:55AM	Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet (Zacks)
Nov-18-24 09:55AM	Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade (Zacks)
Nov-14-24 02:15AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-13-24 05:30PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
08:30AM	Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors (GlobeNewswire)
Nov-07-24 10:00AM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Nov-06-24 04:30PM	Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 (GlobeNewswire)
Nov-05-24 08:30AM	Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer (GlobeNewswire)
Oct-30-24 06:39AM	Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? (Zacks)
Oct-17-24 08:30AM	Tarsus Launches Your Mitey Problem, the First Direct-to-Consumer TV Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% (GlobeNewswire)
Oct-09-24 05:56PM	Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ... (GuruFocus.com)
Sep-25-24 05:00PM	Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 (GlobeNewswire)
Aug-28-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference (GlobeNewswire)
Aug-08-24 09:56PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +13.72%
06:05PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
Jul-29-24 04:30PM	Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
May-29-24 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference (GlobeNewswire) -8.86% +8.70%
12:48PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:06AM	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating (MT Newswires)
03:49AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-08-24 08:58PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
May-06-24 09:55AM	Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect? (Zacks)
May-01-24 05:00PM	Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 (GlobeNewswire) +6.59%
Apr-23-24 08:30AM	Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon (GlobeNewswire)
Apr-09-24 07:35AM	5 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 09:55AM	Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know (Zacks)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why (Zacks)
Mar-06-24 09:55AM	How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% (Zacks)
Mar-05-24 04:30PM	Tarsus to Participate at Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Tarsus Introduces Mite Party Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis (GlobeNewswire)
Mar-01-24 12:07AM	Tarsus Announces Pricing of $100.0 Million Public Offering (GlobeNewswire)
Feb-29-24 04:37PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Feb-28-24 12:00PM	Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy (Zacks)
09:58AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:13PM	Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +18.28%
06:34AM	Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results (GuruFocus.com)
06:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Feb-22-24 08:00AM	Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept Tick-Kill Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease (GlobeNewswire)
Feb-20-24 05:00PM	Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 (GlobeNewswire)
Jan-31-24 05:00PM	Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference (GlobeNewswire) +6.17%
Jan-30-24 04:06AM	Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Jan-21-24 07:01AM	11 Stocks That Will Make You Rich in 5-10 Years (Insider Monkey)
Dec-21-23 03:32PM	Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade (Investor's Business Daily)
Dec-11-23 08:00AM	Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites (GlobeNewswire)

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Azamian Bobak R.	President/CEO and Board Chair	Sep 24 '25	Sale	55.37	6,000	332,220	812,106	Sep 26 04:08 PM
Bobak Azamian Living Trust	Officer	Sep 24 '25	Proposed Sale	55.37	6,000	332,208		Sep 24 04:57 PM
LINK WILLIAM J PHD	Director	Sep 08 '25	Sale	57.00	27,116	1,545,612	143,332	Sep 10 05:03 PM
LINK WILLIAM J PHD	Director	Sep 08 '25	Proposed Sale	57.01	27,116	1,546,000		Sep 08 04:19 PM
Azamian Bobak R.	President/CEO and Board Chair	Aug 11 '25	Sale	50.00	6,000	300,000	818,106	Aug 13 04:32 PM
Azamian Bobak R.	Officer	Aug 11 '25	Proposed Sale	50.00	6,000	300,000		Aug 11 12:43 PM
Farrow Jeffrey S	See Remarks	Jun 17 '25	Sale	40.42	13,608	550,035	36,704	Jun 18 04:07 PM
Farrow Jeffrey S	Officer	Jun 17 '25	Proposed Sale	40.42	13,608	550,088		Jun 17 04:14 PM
Lin Elizabeth Yeu	Chief Medical Officer	Jun 16 '25	Sale	41.08	1,006	41,326	7,694	Jun 17 04:07 PM
Lin Elizabeth Yeu	Officer	Jun 16 '25	Proposed Sale	41.07	1,006	41,321		Jun 16 03:07 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 09 '25	Sale	43.76	17,500	765,800	47,557	Jun 11 04:50 PM
Mottiwala Aziz	Officer	Jun 09 '25	Proposed Sale	44.74	17,500	782,950		Jun 09 10:21 AM
Azamian Bobak R.	President/CEO and Board Chair	Mar 24 '25	Sale	50.00	6,000	300,000	824,106	Mar 26 04:47 PM
Azamian Bobak R.	Officer	Mar 24 '25	Proposed Sale	50.00	6,000	300,000		Mar 24 05:35 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '25	Sale	46.29	3,643	168,634	71,979	Mar 20 09:49 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 20 '25	Sale	50.11	3,365	168,620	65,057	Mar 20 09:49 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 19 '25	Sale	47.40	3,557	168,602	68,422	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 20 '25	Sale	50.11	2,435	122,018	79,682	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '25	Sale	46.29	2,605	120,585	84,660	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 19 '25	Sale	47.40	2,543	120,538	82,117	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 18 '25	Sale	46.29	3,341	154,655	58,057	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 19 '25	Sale	47.40	3,261	154,571	54,796	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 20 '25	Sale	50.11	3,084	154,539	51,712	Mar 20 09:49 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '25	Sale	46.29	2,315	107,161	50,751	Mar 20 09:48 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 20 '25	Sale	50.11	2,137	107,085	46,355	Mar 20 09:48 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 19 '25	Sale	47.40	2,259	107,077	48,492	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 20 '25	Sale	50.11	8,534	427,639	53,635	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 19 '25	Sale	47.40	8,551	405,317	62,169	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '25	Sale	46.29	7,131	330,094	70,720	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 19 '25	Sale	47.40	1,254	59,440	23,617	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 18 '25	Sale	46.29	1,284	59,436	24,871	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 20 '25	Sale	50.11	1,186	59,430	22,431	Mar 20 09:48 PM
Whitfield Dianne C.	Officer	Mar 20 '25	Proposed Sale	50.11	2,137	107,093		Mar 20 04:35 PM
Farrow Jeffrey S	Officer	Mar 20 '25	Proposed Sale	50.11	1,186	59,435		Mar 20 04:30 PM
Mottiwala Aziz	Officer	Mar 20 '25	Proposed Sale	50.11	3,365	168,632		Mar 20 04:29 PM
Wahl Bryan	Officer	Mar 20 '25	Proposed Sale	50.11	3,084	154,550		Mar 20 04:21 PM
Neervannan Seshadri	Officer	Mar 20 '25	Proposed Sale	50.11	2,435	122,026		Mar 20 04:18 PM
Azamian Bobak R.	Officer	Mar 20 '25	Proposed Sale	50.11	8,534	427,669		Mar 20 04:11 PM
Neervannan Seshadri	Officer	Mar 19 '25	Proposed Sale	47.40	2,543	120,536		Mar 19 03:27 PM
Wahl Bryan	Officer	Mar 19 '25	Proposed Sale	47.40	3,261	154,569		Mar 19 03:24 PM
Azamian Bobak R.	Officer	Mar 19 '25	Proposed Sale	47.40	8,551	405,311		Mar 19 03:23 PM
Whitfield Dianne C.	Officer	Mar 19 '25	Proposed Sale	47.40	2,259	107,075		Mar 19 03:22 PM
Farrow Jeffrey S	Officer	Mar 19 '25	Proposed Sale	47.40	1,254	59,439		Mar 19 03:12 PM
Mottiwala Aziz	Officer	Mar 19 '25	Proposed Sale	47.40	3,557	168,599		Mar 19 03:12 PM
Neervannan Seshadri	Officer	Mar 18 '25	Proposed Sale	46.28	2,605	120,571		Mar 18 04:31 PM
Wahl Bryan	Officer	Mar 18 '25	Proposed Sale	46.28	3,341	154,637		Mar 18 04:26 PM
Mottiwala Aziz	Officer	Mar 18 '25	Proposed Sale	46.28	3,643	168,614		Mar 18 04:26 PM
Whitfield Dianne C.	Officer	Mar 18 '25	Proposed Sale	46.28	2,315	107,149		Mar 18 04:20 PM
Azamian Bobak R.	Officer	Mar 18 '25	Proposed Sale	46.28	7,131	330,055		Mar 18 04:15 PM
Farrow Jeffrey S	Officer	Mar 18 '25	Proposed Sale	46.28	1,284	59,429		Mar 18 04:12 PM
Goldberg Andrew D.	Director	Mar 07 '25	Option Exercise	12.89	7,000	90,230	13,350	Mar 11 04:01 PM

Open in Screener

PASG

Passage Bio Inc

Nov 28 • 01:30PM ET

8.83

-0.16 -1.78 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP ADPT NTLA QURE EDIT CLLS BLUE REPL MGTX

| Held by: VTI VXF DFAC

Index	-	P/E	-	EPS (ttm)	-14.46	Insider Own	4.90%	Shs Outstand	3.18M	Perf Week	18.68%
Market Cap	27.55M	Forward P/E	-	EPS next Y	-4.94	Insider Trans	-73.44%	Shs Float	2.97M	Perf Month	18.84%
Enterprise Value	-0.88M	PEG	-	EPS next Q	-2.57	Inst Own	48.15%	Short Float	3.04%	Perf Quarter	23.84%
Income	-45.26M	P/S	-	EPS this Y	54.07%	Inst Trans	0.67%	Short Ratio	2.35	Perf Half Y	1.19%
Sales	0.00M	P/B	0.90	EPS next Y	49.75%	ROA	-48.69%	Short Interest	0.09M	Perf YTD	-22.15%
Book/sh	9.79	P/C	0.52	EPS next 5Y	46.36%	ROE	-87.18%	52W High	26.60 -66.80%	Perf Year	-28.90%
Cash/sh	16.91	P/FCF	-	EPS past 3/5Y	32.43% -1.48%	ROIC	-87.19%	52W Low	5.12 72.33%	Perf 3Y	-63.21%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.10% 10.78%	Perf 5Y	-97.41%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	38.42%	Oper. Margin	-	ATR (14)	0.84	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.51	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.09	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.51	EPS Q/Q	61.07%	SMA20	11.62%	Beta	1.84	Target Price	39.60
Payout	-	Debt/Eq	0.78	Sales Q/Q	-	SMA50	11.20%	Rel Volume	0.48	Prev Close	8.99
Employees	60	LT Debt/Eq	0.67	Earnings	Nov 10 AMC	SMA200	15.12%	Avg Volume	38.34K	Price	8.83
IPO	Feb 28, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	11.51% -	Trades		Volume	18,478	Change	-1.78%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-24	Resumed	Wedbush	Outperform	$3 → $4
Sep-03-24	Initiated	Rodman & Renshaw	Buy	$7
Mar-08-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-19-22	Downgrade	Goldman	Buy → Neutral	$29 → $6
Jul-01-21	Initiated	Raymond James	Outperform	$29
Jun-15-21	Initiated	BTIG Research	Buy	$25
Mar-04-21	Upgrade	Goldman	Neutral → Buy	$28 → $30
Feb-04-21	Initiated	Guggenheim	Buy	$25
Jan-25-21	Initiated	Wedbush	Outperform	$26
Jan-04-21	Upgrade	JP Morgan	Neutral → Overweight	$25 → $35
Dec-11-20	Initiated	Citigroup	Neutral	$28
Aug-14-20	Downgrade	JP Morgan	Overweight → Neutral	$25
Jun-25-20	Downgrade	Goldman	Buy → Neutral	$28
Mar-25-20	Initiated	Chardan Capital Markets	Buy	$30
Mar-24-20	Initiated	JP Morgan	Overweight	$25
Mar-24-20	Initiated	Goldman	Buy	$27
Mar-24-20	Initiated	Cowen	Outperform

Show Previous Ratings

Nov-10-25 04:15PM	Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire) +6.68% +14.84%
Nov-05-25 07:00AM	Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-14-25 07:00AM	Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-01-25 09:55AM	Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet (Zacks)
Aug-28-25 07:00AM	Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
09:55AM	Loading…
Aug-15-25 09:55AM	Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade (Zacks) -8.43%
09:25AM	Passage Bio price target lowered to $67 from $260 at Canaccord (TipRanks)
Aug-12-25 07:00AM	Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Jul-10-25 07:00AM	Passage Bio Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -9.86%
Jun-23-25 07:00AM	Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update (GlobeNewswire) -14.37%
May-13-25 07:00AM	Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-07-25 12:00PM	Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-04-25 07:00AM	Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -11.37%
Feb-26-25 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-10-25 07:00AM	Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates (GlobeNewswire)
06:55AM	Loading…
Nov-30-24 06:55AM	Passage Bio assumed with an Outperform at Wedbush (TipRanks)
Nov-14-24 07:29AM	Passage Bio Achieves Milestones in Gene Therapy Trials (TipRanks)
Nov-13-24 07:00AM	Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -12.87%
Nov-06-24 07:00AM	Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-24-24 07:00AM	Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference (GlobeNewswire) +11.40%
Sep-23-24 09:36PM	Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc (GuruFocus.com) -5.11%
07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-19-24 01:25AM	Orbimed Advisors LLC Reduces Stake in Passage Bio Inc (GuruFocus.com)
Sep-16-24 07:00AM	Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) (GlobeNewswire) -9.45%
Sep-10-24 07:52AM	Passage Bio Welcomes Tom Kassberg to Board of Directors (GlobeNewswire) +6.06%
Aug-30-24 07:00AM	Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.96%
Aug-08-24 07:00AM	Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.22%
Aug-06-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 12:30PM	Jim Wilson, prominent gene therapy researcher, to depart UPenn (BioPharma Dive) +6.63%
07:00AM	Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration (GlobeNewswire)
07:13AM	Loading…
Jul-25-24 07:13AM	Passage Bio targets FDA to greenlight ALS gene therapy trial (Clinical Trials Arena) +6.23%
Jul-16-24 07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients (GlobeNewswire)
Jun-18-24 09:35AM	Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.45%
Jun-05-24 07:30AM	Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 08:00AM	Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award (GlobeNewswire)
May-16-24 12:00PM	All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy (Zacks)
May-14-24 01:54PM	PASG Stock Earnings: Passage Bio Beats EPS for Q1 2024 (InvestorPlace) -10.47%
07:00AM	Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Apr-22-24 07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-07-24 12:00PM	Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know (Zacks) -6.43%
Mar-06-24 01:52PM	PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023 (InvestorPlace)
Mar-05-24 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Mar-04-24 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Feb-27-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.12%
Feb-01-24 07:09PM	7 Analyst-Backed Stocks With Promising 10-Bagger Potential (InvestorPlace) +5.13%
Jan-31-24 07:30AM	Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-25-23 10:14PM	7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight (InvestorPlace)
Dec-20-23 07:00AM	Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities (GlobeNewswire) +7.35%
Nov-17-23 04:30PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-13-23 07:00AM	Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Oct-30-23 07:00AM	Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire) +6.91%
Oct-20-23 04:30PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-11-23 10:04AM	Lab Notes: Almac Group starts work on $65M Montco expansion expected to create 355 jobs (American City Business Journals)
Aug-07-23 07:15AM	Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.11%
07:00AM	Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Aug-01-23 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-31-23 07:00AM	Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors (GlobeNewswire)
Jul-24-23 12:37PM	Passage Bio reduces staff by 26% in latest round of job cuts (American City Business Journals) -5.31%
Jul-06-23 11:17AM	12 Best Nano Cap Stocks To Buy Now (Insider Monkey)
Jun-05-23 07:00AM	Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-11-23 07:00AM	Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
May-04-23 07:00AM	Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award (GlobeNewswire) +5.91%
Apr-21-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-17-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-29-23 09:02AM	Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-27-23 07:00AM	Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-08-23 07:14AM	Passage Bio, Inc. (NASDAQ:PASG) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 12:42AM	Q4 2022 Passage Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-23 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-01-23 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Feb-28-23 07:00AM	Passage Bio to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-27-23 07:00AM	Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023 (GlobeNewswire) +7.69%
Feb-24-23 07:00AM	Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire) -7.87%
Feb-20-23 05:59PM	'We've turned the page': CEO says Passage Bio is building momentum after turbulent 2022 (American City Business Journals)
Feb-15-23 07:00AM	Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire)
Jan-20-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-23 07:39AM	After losing 67% in the past year, Passage Bio, Inc. (NASDAQ:PASG) institutional owners must be relieved by the recent gain (Simply Wall St.)
Dec-14-22 12:13PM	Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder (Benzinga) +9.65%
07:00AM	Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Nov-21-22 05:24AM	Estimating The Fair Value Of Passage Bio, Inc. (NASDAQ:PASG) (Simply Wall St.)
Nov-10-22 07:00AM	Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +10.83%
Nov-08-22 07:00AM	Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Nov-03-22 07:30AM	Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire)
Oct-14-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.88%
Oct-11-22 12:25PM	Here's Why Passage Bio (NASDAQ:PASG) Must Use Its Cash Wisely (Simply Wall St.)
Oct-10-22 07:00AM	Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer (GlobeNewswire)
Sep-26-22 07:00AM	Passage Bio to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-19-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-11-22 07:00AM	Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations (GlobeNewswire)
Aug-05-22 07:00AM	Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Aug-04-22 07:00AM	Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Jul-28-22 07:30AM	Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire) -7.98%
Jul-21-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-12-22 08:19AM	What Kind Of Investors Own Most Of Passage Bio, Inc. (NASDAQ:PASG)? (Simply Wall St.)
Jul-06-22 07:00AM	Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors (GlobeNewswire)
Jun-09-22 07:30AM	Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
Jun-08-22 07:30AM	Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy (GlobeNewswire)
Jun-01-22 10:19AM	Passage Bio and CEO Bruce Goldsmith part ways (American City Business Journals)

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	Sep 12 '25	Buy	6.99	19,783	138,299	611,804	Sep 15 08:05 PM
Lynx1 Capital Management LP	10% Owner	Sep 15 '25	Buy	6.99	11,900	83,175	623,704	Sep 15 08:05 PM
Lynx1 Capital Management LP	10% Owner	Sep 11 '25	Buy	6.96	325	2,261	592,021	Sep 15 08:05 PM
Lynx1 Capital Management LP	10% Owner	Jul 24 '25	Buy	5.71	66,423	379,455	591,696	Jul 24 06:12 PM
Lynx1 Capital Management LP	10% Owner	Jul 23 '25	Buy	5.74	49,302	283,033	525,273	Jul 24 06:12 PM
Lynx1 Capital Management LP	10% Owner	Jul 22 '25	Buy	5.44	13,123	71,338	475,971	Jul 24 06:12 PM
OrbiMed Private Investments VI	Stockholder	Jul 21 '25	Proposed Sale	5.56	132,645	737,506		Jul 21 05:33 PM
OrbiMed Private Investments VI	Stockholder	Jul 15 '25	Proposed Sale	6.79	53,293	361,859		Jul 15 08:17 PM
OrbiMed Private Investments VI	Stockholder	Jul 07 '25	Proposed Sale	0.43	259,000	112,147		Jul 07 06:02 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 24 '25	Sale	0.35	231,600	81,060	6,418,400	Jun 26 05:10 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 26 '25	Sale	0.33	213,257	70,375	6,066,343	Jun 26 05:10 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 25 '25	Sale	0.33	138,800	45,804	6,279,600	Jun 26 05:10 PM
OrbiMed Private Investments VI	Stockholder	Jun 24 '25	Proposed Sale	0.35	1,076,120	378,364		Jun 24 06:48 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 23 '25	Sale	0.34	89,328	30,372	6,718,195	Apr 24 05:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 22 '25	Sale	0.34	78,049	26,537	6,807,523	Apr 24 05:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 24 '25	Sale	0.32	68,195	21,822	6,650,000	Apr 24 05:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 17 '25	Sale	0.33	77,090	25,440	6,885,572	Apr 17 06:10 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 16 '25	Sale	0.33	61,638	20,341	6,962,662	Apr 17 06:10 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 15 '25	Sale	0.38	10,326	3,924	7,024,300	Apr 17 06:10 PM
OrbiMed Private Investments VI	Stockholder	Apr 15 '25	Proposed Sale	0.38	787,179	301,490		Apr 15 05:40 PM
Borthwick Kathleen	CFO	Feb 11 '25	Sale	0.53	3,183	1,686	41,283	Feb 12 04:21 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 10 '25	Sale	0.66	126,209	83,298	7,131,636	Jan 14 05:17 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 14 '25	Sale	0.60	79,024	47,414	7,034,626	Jan 14 05:17 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 13 '25	Sale	0.64	17,986	11,511	7,113,650	Jan 14 05:17 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 08 '25	Sale	0.68	75,007	51,005	7,257,845	Jan 08 06:09 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 07 '25	Sale	0.71	52,536	37,301	7,332,852	Jan 08 06:09 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 06 '25	Sale	0.77	19,481	15,000	7,385,388	Jan 08 06:09 PM
OrbiMed Private Investments VI	Stockholder	Jan 06 '25	Proposed Sale	0.83	1,140,740	945,673		Jan 06 04:57 PM
Lynx1 Capital Management LP	10% Owner	Dec 27 '24	Buy	0.65	373,645	241,038	9,256,953	Dec 31 04:05 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 20 '24	Sale	0.60	230,321	138,193	7,404,869	Dec 26 04:34 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 09 '24	Sale	0.84	54,181	45,512	7,643,285	Dec 11 05:32 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 10 '24	Sale	0.80	8,015	6,412	7,635,270	Dec 11 05:32 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 11 '24	Sale	0.80	80	64	7,635,190	Dec 11 05:32 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 04 '24	Sale	0.79	76,200	60,198	7,718,369	Dec 06 07:07 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 06 '24	Sale	0.82	20,903	17,140	7,697,466	Dec 06 07:07 PM
OrbiMed Private Investments VI	Stockholder	Dec 04 '24	Proposed Sale	0.89	2,985,518	2,657,111		Dec 04 07:03 PM
Worldwide Healthcare Trust PLC	Stockholder	Dec 04 '24	Proposed Sale	0.89	2,028,307	1,805,193		Dec 04 06:57 PM

Open in Screener

PHAT

Phathom Pharmaceuticals Inc

Nov 28 • 04:00PM ET

15.62

+0.45 2.97 %

Healthcare • Biotechnology • USA • NASD

PHAT Phathom Pharmaceuticals Inc daily Stock Chart

Peers: NBIX BPMC AXSM BTAI ACAD VKTX MDGL PTGX RDUS XENE

| Held by: VTI IWM VXF SURI IBB DWAS IWN SCHA VTWO XPH

Index	RUT	P/E	-	EPS (ttm)	-3.81	Insider Own	41.92%	Shs Outstand	71.04M	Perf Week	8.77%
Market Cap	1.11B	Forward P/E	-	EPS next Y	-0.73	Insider Trans	-0.01%	Shs Float	41.32M	Perf Month	15.45%
Enterprise Value	1.56B	PEG	-	EPS next Q	-0.42	Inst Own	50.73%	Short Float	31.65%	Perf Quarter	28.24%
Income	-274.55M	P/S	7.55	EPS this Y	40.34%	Inst Trans	3.12%	Short Ratio	11.75	Perf Half Y	267.53%
Sales	147.19M	P/B	-	EPS next Y	76.76%	ROA	-87.53%	Short Interest	13.08M	Perf YTD	92.36%
Book/sh	-5.95	P/C	8.22	EPS next 5Y	-	ROE	-	52W High	16.08 -2.86%	Perf Year	71.84%
Cash/sh	1.90	P/FCF	-	EPS past 3/5Y	-10.82% 12.50%	ROIC	-202.37%	52W Low	2.21 606.79%	Perf 3Y	60.21%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	87.25%	Volatility	4.84% 7.15%	Perf 5Y	-63.85%
Dividend TTM	-	EV/Sales	10.59	EPS Y/Y TTM	33.03%	Oper. Margin	-145.03%	ATR (14)	0.89	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.19	Sales Y/Y TTM	460.30%	Profit Margin	-186.53%	RSI (14)	67.23	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	2.23	EPS Q/Q	69.16%	SMA20	9.02%	Beta	0.43	Target Price	23.12
Payout	-	Debt/Eq	-	Sales Q/Q	202.74%	SMA50	18.25%	Rel Volume	0.69	Prev Close	15.17
Employees	427	LT Debt/Eq	-	Earnings	Oct 30 BMO	SMA200	78.36%	Avg Volume	1.11M	Price	15.62
IPO	Oct 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.45% 5.34%	Trades		Volume	765,735	Change	2.97%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-25	Initiated	Cantor Fitzgerald	Overweight	$23
May-03-24	Initiated	Stifel	Buy	$24
Jan-05-24	Reiterated	Needham	Buy	$23 → $26
Aug-09-23	Initiated	H.C. Wainwright	Buy	$28
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy	$21
Oct-21-22	Initiated	Jefferies	Buy	$16
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral	$40 → $48
Feb-17-21	Initiated	BMO Capital Markets	Outperform	$63
Feb-02-21	Initiated	Guggenheim	Buy	$60
Jun-26-20	Downgrade	Goldman	Neutral → Sell	$34
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Needham	Buy	$40
Nov-19-19	Initiated	Jefferies	Buy	$32
Nov-19-19	Initiated	Goldman	Neutral	$32

Show Previous Ratings

Nov-04-25 08:00AM	Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA (vonoprazan) in Eosinophilic Esophagitis (EoE) (GlobeNewswire)
Nov-03-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-25 04:24PM	Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:49AM	Loading…
Oct-29-25 09:49AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-25-25 09:59AM	Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease (GlobeNewswire)
Oct-23-25 08:00AM	Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting (GlobeNewswire)
Oct-20-25 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 (GlobeNewswire) +8.10%
Oct-06-25 08:00AM	Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer (GlobeNewswire)
Sep-18-25 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why (Zacks) +6.82%
Sep-08-25 05:04PM	Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High? (Zacks)
Aug-25-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-25 09:55AM	Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet (Zacks) +8.77%
Aug-20-25 08:00AM	Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing (GlobeNewswire)
08:10AM	Loading…
Aug-07-25 08:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.29%
06:59AM	Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-25 08:25AM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
Aug-04-25 08:15AM	Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-28-25 08:00AM	Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 (GlobeNewswire) -8.62%
Jun-23-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.12%
07:59AM	Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Jun-16-25 08:00AM	Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets Through May 3, 2032 (GlobeNewswire)
Jun-09-25 09:55AM	Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade (Zacks)
Jun-06-25 12:45PM	Phathom Pharmaceuticals shares soar on FDA exclusivity grant (Investing.com) +90.19%
12:27PM	Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 (GlobeNewswire)
May-15-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.08%
May-08-25 09:35AM	After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) (Zacks)
May-02-25 03:02AM	Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com) -17.86%
May-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -21.68%
12:09PM	Loading…
12:09PM	Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:59AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2025 Annual Meeting (GlobeNewswire)
Apr-23-25 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 (GlobeNewswire)
Apr-16-25 08:00AM	Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors (GlobeNewswire) -11.43%
Apr-08-25 07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks) -12.73%
Apr-03-25 11:25AM	Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (Seeking Alpha) -8.83%
08:00AM	Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -18.34% +7.23%
08:00AM	Phathom Pharmaceuticals Announces Leadership Succession (GlobeNewswire)
Mar-31-25 07:59AM	Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA (vonoprazan) (GlobeNewswire) -5.00%
Mar-07-25 02:08AM	Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... (GuruFocus.com) -14.24%
Mar-06-25 09:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-25 07:21AM	Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result (GuruFocus.com) +8.96%
Feb-24-25 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 (GlobeNewswire) -5.82%
Jan-29-25 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Dec-12-24 09:39AM	Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? (Insider Monkey)
Dec-11-24 08:00AM	Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA (vonoprazan) Tablets (GlobeNewswire) -5.99%
Dec-06-24 09:35AM	Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround (Zacks) +5.88%
Nov-19-24 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know (Zacks) +5.40%
Nov-08-24 06:02AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -8.86%
Nov-07-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:21AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-04-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 (GlobeNewswire) +8.29%
Oct-27-24 12:00PM	Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting (GlobeNewswire)
Aug-29-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-24 08:00AM	Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Aug-08-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.70%
08:00AM	Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-30-24 08:00AM	Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients (GlobeNewswire)
Jul-29-24 07:59AM	Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults (GlobeNewswire) -7.68%
Jun-09-24 07:00AM	Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now (InvestorPlace)
Jun-07-24 06:17AM	Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze (InvestorPlace) +9.50%
May-28-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-24 08:00AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2024 Annual Meeting (GlobeNewswire)
May-13-24 11:02AM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 08:00AM	The 3 Best Healthcare Stocks to Buy in May 2024 (InvestorPlace) -5.60%
May-09-24 09:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 08:02AM	Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target (MT Newswires)
Apr-29-24 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-22-24 03:30AM	SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT (PR Newswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com) -5.38%
11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 08:00AM	Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 08:00AM	Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, VOQUEZNA Can Kick Some Acid (GlobeNewswire)
Mar-08-24 03:05PM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:57AM	Q4 2023 Phathom Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 01:51PM	PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -6.58%
01:38PM	Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ... (GuruFocus.com)
08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024 (GlobeNewswire)
Feb-13-24 08:00AM	Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients (GlobeNewswire)
Jan-31-24 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-14-23 08:00AM	Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital (GlobeNewswire) +7.98%
Dec-06-23 08:00AM	Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD (GlobeNewswire) -5.36%
Nov-28-23 08:00AM	Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn (GlobeNewswire)
Nov-09-23 09:34AM	Phathom Pharmaceuticals Inc (PHAT) Reports Q3 2023 Financial Results (GuruFocus.com)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates (GlobeNewswire)
Nov-01-23 05:00PM	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults (GlobeNewswire) -16.96%
Oct-30-23 08:00AM	Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults (GlobeNewswire)
Oct-25-23 08:01AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-26-23 08:01AM	Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD (GlobeNewswire)
Sep-05-23 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.27%

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Breedlove Robert Charles	Principal Accounting Officer	Nov 03 '25	Sale	13.51	524	7,079	47,407	Nov 05 04:30 PM
Basta Steven L	President and CEO	Sep 25 '25	Option Exercise	0.00	90,000	0	90,000	Sep 26 07:03 PM
Breedlove Robert Charles	Principal Accounting Officer	Sep 05 '25	Sale	12.09	461	5,573	47,931	Sep 09 04:40 PM
Breedlove Robert Charles	Principal Accounting Officer	Jul 16 '25	Sale	8.36	1,692	14,152	48,392	Jul 18 04:05 PM
Topper James N	Director	May 21 '25	Buy	3.86	3,780	14,609	59,403	May 23 04:06 PM
Topper James N	Director	May 14 '25	Buy	3.32	6,300	20,919	55,623	May 15 04:17 PM
Topper James N	Director	May 13 '25	Buy	3.16	1,120	3,543	49,323	May 15 04:17 PM
Topper James N	Director	May 09 '25	Buy	3.22	35,602	114,616	35,602	May 13 04:13 PM
Topper James N	Director	May 12 '25	Buy	3.04	12,601	38,301	48,203	May 13 04:13 PM
Parikh Asit	Director	May 06 '25	Buy	2.60	5,000	13,000	90,500	May 08 05:27 PM
Parikh Asit	Director	May 07 '25	Buy	2.40	5,000	11,984	95,500	May 08 05:27 PM
Henderson Molly	CFO and CBO	Apr 07 '25	Sale	4.55	3,678	16,740	89,868	Apr 08 05:01 PM
Parikh Asit	Director	Mar 13 '25	Buy	4.42	10,000	44,200	85,500	Mar 17 04:27 PM
Henderson Molly	CFO and CBO	Jan 21 '25	Sale	6.59	6,583	43,371	93,546	Jan 23 04:24 PM
Nabulsi Azmi	Chief Operating Officer	Jan 21 '25	Sale	6.59	7,886	51,957	233,390	Jan 23 04:21 PM
Curran Terrie	President and Chief Executive	Jan 21 '25	Sale	6.59	19,109	125,884	360,465	Jan 23 04:19 PM
Nabulsi Azmi	Chief Operating Officer	Dec 19 '24	Sale	8.00	1,118	8,944	239,303	Dec 20 04:21 PM
Henderson Molly	CFO and CBO	Dec 19 '24	Sale	8.00	1,291	10,328	98,156	Dec 20 04:20 PM
KARBE FRANK	Director	Dec 13 '24	Buy	7.93	12,500	99,084	57,000	Dec 16 08:05 AM
Parikh Asit	Director	Dec 13 '24	Buy	8.12	10,000	81,248	75,500	Dec 16 08:05 AM

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

Nov 28 • 01:30PM ET

73.05

-0.08 -0.11 %

Healthcare • Biotechnology • USA • NASD

MIRM Mirum Pharmaceuticals Inc daily Stock Chart

Peers: VRTX GILD AKRO ENTA MDGL PTCT NBIX VKTX DVAX GLMD

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-0.86	Insider Own	18.20%	Shs Outstand	51.31M	Perf Week	5.62%
Market Cap	3.75B	Forward P/E	195.49	EPS next Y	0.37	Insider Trans	-1.88%	Shs Float	42.04M	Perf Month	3.68%
Enterprise Value	3.70B	PEG	-	EPS next Q	-0.05	Inst Own	96.10%	Short Float	18.22%	Perf Quarter	-1.11%
Income	-41.42M	P/S	7.96	EPS this Y	79.67%	Inst Trans	4.15%	Short Ratio	11.44	Perf Half Y	64.31%
Sales	471.79M	P/B	12.84	EPS next Y	199.36%	ROA	-5.70%	Short Interest	7.66M	Perf YTD	76.66%
Book/sh	5.69	P/C	10.00	EPS next 5Y	-	ROE	-15.81%	52W High	78.54 -7.00%	Perf Year	65.01%
Cash/sh	7.31	P/FCF	84.71	EPS past 3/5Y	12.58% 4.14%	ROIC	-6.80%	52W Low	36.88 98.07%	Perf 3Y	270.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	160.13% -	Gross Margin	79.85%	Volatility	3.22% 4.22%	Perf 5Y	264.70%
Dividend TTM	-	EV/Sales	7.84	EPS Y/Y TTM	58.63%	Oper. Margin	-8.86%	ATR (14)	2.67	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.16	Sales Y/Y TTM	53.66%	Profit Margin	-8.78%	RSI (14)	56.01	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	3.31	EPS Q/Q	117.12%	SMA20	3.03%	Beta	0.43	Target Price	88.00
Payout	-	Debt/Eq	1.09	Sales Q/Q	47.17%	SMA50	1.59%	Rel Volume	0.16	Prev Close	73.13
Employees	322	LT Debt/Eq	1.08	Earnings	Nov 04 AMC	SMA200	28.77%	Avg Volume	669.94K	Price	73.05
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	135.66% 1.93%	Trades		Volume	104,629	Change	-0.11%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Initiated	TD Cowen	Buy	$95
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-25 08:10AM	Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
12:04AM	Loading…
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
Oct-28-25 04:02PM	Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (Business Wire)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 07:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-10-25 06:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Loading…
Sep-08-25 08:00AM	Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study (Business Wire)
Aug-27-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-25 05:31PM	IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies \| DelveInsight (PR Newswire) +9.84%
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) +12.04%
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-10-25 06:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-24-25 12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-17-25 12:36PM	Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up (Investor's Business Daily)
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
11:30AM	Loading…
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
Jun-10-25 08:40PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-25 11:31AM	Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? (Zacks)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
May-19-25 08:30AM	Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer (Business Wire)
May-14-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Data from Mirums VANTAGE PBC Study Showcased at EASL (Business Wire)
May-08-25 12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks) +9.75%
07:08AM	Q1 2025 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:29AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-07-25 09:17PM	Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth (Seeking Alpha)
09:17PM	Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-06-25 05:05PM	Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.13%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-04-25 06:45PM	Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities (Seeking Alpha)
Apr-30-25 08:30AM	Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (Business Wire)
Apr-28-25 08:30AM	Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses (Business Wire)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-14-25 08:30AM	Mirums LIVMARLI Now FDA Approved in Tablet Formulation (Business Wire)
Apr-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.67%
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
Mar-28-25 11:30AM	Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-27-25 08:30AM	LIVMARLI Now Approved in Japan for ALGS and PFIC (Business Wire)
Mar-24-25 05:17PM	Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (SeekingAlpha)
12:24PM	Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (SeekingAlpha)
Mar-21-25 12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
Mar-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 10:56AM	Q4 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.02%
02:22AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Feb-26-25 05:15PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update (Business Wire)
11:48AM	Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
09:55AM	Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know (Zacks)
Feb-24-25 08:30AM	Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) (Business Wire)
07:31AM	Mirum drug for rare genetic disease gains FDA approval (BioPharma Dive)
Feb-19-25 04:04PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 (Business Wire)
Feb-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-24-25 12:00PM	Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-14-25 08:50AM	Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-13-25 08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates (Business Wire) +6.49%
Jan-10-25 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-06-25 04:04PM	Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 11:30AM	Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? (Zacks)
Dec-10-24 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-06-24 06:46AM	Mirum Pharmaceuticals price target raised to $74 from $69 at JMP Securities (TipRanks)
Nov-14-24 08:00AM	Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire) +5.33%
Nov-13-24 02:09AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Nov-12-24 09:15AM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-08-24 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-24 04:30PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-04-24 04:30PM	Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 (Business Wire)
Oct-31-24 10:02AM	Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know (Zacks)
08:30AM	Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting (Business Wire)
Oct-23-24 08:49AM	Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth (Insider Monkey)
Oct-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis (Business Wire)
Oct-09-24 05:18PM	Mirum Pharmaceuticals Inc (MIRM) Q2 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Sep-10-24 08:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
11:31AM	Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-19-24 11:06AM	Mirum (MIRM) Banks on Livmarli, Overdependence a Concern (Zacks)
Aug-09-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.79%
Aug-08-24 11:01AM	Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top (Zacks)
Aug-07-24 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GREY MICHAEL G	Director	Nov 21 '25	Option Exercise	2.94	50,000	146,800	50,000	Nov 25 04:10 PM
GREY MICHAEL G	Director	Nov 21 '25	Sale	70.00	50,000	3,500,000	0	Nov 25 04:10 PM
MICHAEL GREY	Director	Nov 21 '25	Proposed Sale	70.00	50,000	3,500,000		Nov 21 04:09 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Option Exercise	19.24	19,133	368,119	158,034	Nov 20 04:21 PM
Brege Laura	Director	Sep 11 '25	Option Exercise	15.00	17,000	255,000	32,703	Sep 12 08:00 PM
Brege Laura	Director	Sep 11 '25	Sale	74.40	17,000	1,264,868	15,703	Sep 12 08:00 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 12 '25	Sale	76.01	9,578	728,024	39,945	Sep 12 08:00 PM
LAURA BREGE	Director	Sep 11 '25	Proposed Sale	74.41	17,000	1,264,917		Sep 11 04:04 PM
Ramasastry Saira	Director	Sep 08 '25	Option Exercise	23.51	17,000	399,670	17,000	Sep 10 05:50 PM
SAIRA RAMASASTRY	Director	Sep 08 '25	Proposed Sale	77.04	17,000	1,309,716		Sep 08 04:06 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 12 '25	Option Exercise	26.49	2,954	78,251	31,190	Aug 12 08:00 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 12 07:57 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Sale	62.00	40,000	2,480,000	138,641	Aug 12 07:57 PM
CHRISTOPHER PEETZ	Officer	Aug 11 '25	Proposed Sale	62.00	40,000	2,480,000		Aug 11 04:06 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Option Exercise	6.27	10,000	62,700	12,426	Aug 08 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Sale	58.00	10,000	580,000	2,426	Aug 08 04:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 08 04:49 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Sale	55.25	40,000	2,210,040	138,641	Aug 08 04:49 PM
JOLANDA MARIE HOWE	Officer	Aug 07 '25	Proposed Sale	58.00	10,000	580,000		Aug 07 04:26 PM
CHRISTOPHER PEETZ	Officer	Aug 07 '25	Proposed Sale	55.25	40,000	2,210,040		Aug 07 04:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '25	Sale	48.25	564	27,213	2,903	Jul 03 06:48 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 03 '25	Sale	49.08	477	23,411	2,426	Jul 03 06:48 PM
JOLANDA MARIE HOWE	Officer	Jul 03 '25	Proposed Sale	49.08	477	23,411		Jul 03 01:13 PM
Fairey William	Director	Jun 11 '25	Sale	48.42	3,203	155,091	2,500	Jun 13 04:18 PM
WILLIAM C FAIREY	Director	Jun 11 '25	Proposed Sale	48.42	3,203	155,091		Jun 11 04:05 PM
Ramasastry Saira	Director	Jun 03 '25	Option Exercise	14.12	2,500	35,300	2,500	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 02 '25	Sale	46.20	5,703	263,492	0	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 03 '25	Sale	45.74	2,500	114,352	0	Jun 04 04:11 PM
SAIRA RAMASASTRY	Director	Jun 03 '25	Proposed Sale	45.74	2,500	114,352		Jun 03 05:07 PM
SAIRA RAMASASTRY	Director	Jun 02 '25	Proposed Sale	46.20	5,703	263,492		Jun 02 06:43 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 18 '25	Sale	44.45	2,415	107,343	2,426	Mar 19 05:40 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Option Exercise	2.94	52,900	155,526	59,547	Mar 18 09:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Sale	44.35	57,606	2,554,763	4,841	Mar 18 09:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 17 '25	Sale	44.21	7,879	348,364	18,672	Mar 18 09:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 17 '25	Sale	44.21	27,279	1,206,122	138,641	Mar 18 09:30 PM
Heron Patrick J	Director	Mar 14 '25	Buy	44.11	528	23,291	168,651	Mar 18 05:04 PM
Heron Patrick J	Director	Mar 17 '25	Buy	43.93	21	923	168,672	Mar 18 05:04 PM
JOLANDA MARIE HOWE	Officer	Mar 18 '25	Proposed Sale	44.45	2,415	107,343		Mar 18 04:12 PM
JOLANDA MARIE HOWE	Officer	Mar 17 '25	Proposed Sale	44.36	54,706	2,426,540		Mar 17 04:21 PM
Heron Patrick J	Director	Mar 10 '25	Buy	42.97	1,335	57,363	167,160	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 11 '25	Buy	43.77	963	42,155	168,123	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 06 '25	Buy	43.89	1,335	58,597	165,245	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 07 '25	Buy	43.21	580	25,064	165,825	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 04 '25	Buy	45.57	1,335	60,830	163,643	Mar 06 05:30 PM
Heron Patrick J	Director	Mar 05 '25	Buy	44.55	267	11,894	163,910	Mar 06 05:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 04 '25	Sale	45.58	14,850	676,928	12,111	Mar 05 04:28 PM
Radovich Peter	Officer	Mar 04 '25	Proposed Sale	45.52	14,850	675,956		Mar 04 04:43 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Option Exercise	2.94	40,000	117,440	155,920	Mar 04 04:26 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Sale	46.91	40,000	1,876,353	115,920	Mar 04 04:26 PM
CHRISTOPHER PEETZ	Officer	Mar 03 '25	Proposed Sale	46.91	40,000	1,876,280		Mar 03 04:49 PM
Radovich Peter	PRESIDENT AND COO	Feb 03 '25	Sale	48.22	2,627	126,681	26,961	Feb 04 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 03 '25	Sale	48.22	9,102	438,921	115,920	Feb 04 05:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 03 '25	Sale	48.22	1,064	51,309	4,232	Feb 04 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 24 '25	Sale	47.92	3,177	152,256	29,588	Jan 27 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 24 '25	Sale	47.92	902	43,228	3,524	Jan 27 04:48 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 24 '25	Sale	47.92	6,837	327,658	125,022	Jan 27 04:48 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 17 '25	Sale	45.86	6,969	319,598	5,649	Jan 21 04:21 PM
Radovich Peter	PRESIDENT AND COO	Jan 07 '25	Sale	42.82	1,998	85,545	27,015	Jan 08 04:44 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	42.82	7,489	320,644	119,359	Jan 08 04:42 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 07 '25	Sale	42.82	750	32,111	2,926	Jan 08 04:38 PM

Black Swan Sale

50% Off Elite

TARS

Tarsus Pharmaceuticals Inc

PASG

Passage Bio Inc

PHAT

Phathom Pharmaceuticals Inc

MIRM

Mirum Pharmaceuticals Inc

Upgrade your FINVIZ experience